Reports Q1 revenue $123.876M, consensus $122.71M. “Our Bioventus (BVS) team delivered solid results to start the year and we are making substantial progress with executing our strategic plan,” said Rob Claypoole, Bioventus President and Chief Executive Officer. “We remain well positioned to navigate the uncertain macro-environment while achieving above-market revenue growth through a multitude of diverse growth drivers, enhancing profitability and accelerating cash flow to create significant shareholder value.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BVS:
- BVS Upcoming Earnings Report: What to Expect?
- Bioventus Earnings Call: Strong Growth & 2025 Outlook
- Bioventus: Strong Financial Performance and Strategic Growth Drive Buy Rating
- Bioventus Faces Potential Stock Dilution Risk Amid Resale of 35 Million Shares
- Bioventus Reports Strong 2024 Financial Performance
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue